FindTrial
Sign In

Study on the relationship between hepatocyte growth factor and chronic heart failure

Study on the relationship between hepatocyte growth factor and chronic heart failure

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053825
Enrollment
Unknown
Registered
2021-11-30
Start date
2021-11-17
Completion date
Unknown
Last updated
2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure

Interventions

chronic heart failure patient group:None
healthy group:None

Sponsors

First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for chronic heart failure; 2. NYHA cardiac function classification is I-IV; 3. Aged 18 to 100 years; 4. Agree to participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with heart failure due to failure of important organs such as liver and kidney; 2. Pregnant or breastfeeding patients, allergic constitution and allergic to multiple drugs; 3. Combined with serious primary diseases such as liver, kidney, endocrine system and hematopoietic system; 4. Those with mental disorders and unwilling to cooperate; 5. The patient has participated in other clinical trials within 3 months.

Design outcomes

Primary

MeasureTime frame
hepatocyte growth factor concentration;B-type natriuretic peptide;cardiac ejection fraction;growth stimulating expression factor 2;—

Countries

China

Contacts

Public ContactHu Zeping
1431318679@qq.com+86 13955174705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026